预约演示
更新于：2025-07-14
Hydrochlorothiazide/Telmisartan
替米沙坦氢氯噻嗪
更新于：2025-07-14
概要
基本信息
药物类型 小分子化药 |
别名 Telmisartan and Hydrochlorothiazide、TELMISARTAN/HYDROCHLOROTHIAZIDE、Telmisartan/Hydrochlorothiazide + [14] |
作用方式 拮抗剂、抑制剂 |
作用机制 AT1R拮抗剂(血管紧张素II-1型受体拮抗剂)、NCC抑制剂(噻嗪类敏感氯化钠协同转运蛋白抑制剂) |
治疗领域 |
非在研适应症- |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2000-11-17), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C40H38ClN7O6S2 |
InChIKeyOZCVMXDGSSXWFT-UHFFFAOYSA-N |
CAS号485391-74-0 |
关联
56
项与 替米沙坦氢氯噻嗪 相关的临床试验CTR20242639
南京黄龙生物科技有限公司研制的替米沙坦氢氯噻嗪片（80mg/12.5mg）与Boehringer Ingelheim International GmbH上市的替米沙坦氢氯噻嗪片（美嘉素®，80mg/12.5mg）在中国健康受试者中进行的随机、开放、单剂量、2序列、4周期、交叉、空腹及餐后状态下的生物等效性研究
CTR20242468
替米沙坦氢氯噻嗪片（40 mg/12.5 mg）在健康受试者中空腹/餐后生物等效性试验
CTIS2023-504812-13-00
Effects of single-pill combination of telmisartan/amlodipine and telmisartan/amlodipine/hydrochlorothiazide on 24-hour blood pressure (BP) reduction, 24-h BP variability and office BP control in patients with arterial hypertension – SATELLITE - KCT02/2023-SATELLITE
100 项与 替米沙坦氢氯噻嗪 相关的临床结果
登录后查看更多信息
100 项与 替米沙坦氢氯噻嗪 相关的转化医学
登录后查看更多信息
100 项与 替米沙坦氢氯噻嗪 相关的专利（医药）
登录后查看更多信息
24
项与 替米沙坦氢氯噻嗪 相关的文献（医药）2014-01-20JOURNAL OF LIQUID CHROMATOGRAPHY & RELATED TECHNOLOGIES
QUANTITATIVE DETERMINATION OF FOUR ANGIOTENSIN-II-RECEPTOR ANTAGONISTS IN PRESENCE OF HYDROCHLOROTHIAZIDE BY A GRADIENT TECHNIQUE HPLC IN THEIR PHARMACEUTICAL PREPARATIONS
作者: Elshanawane, Abdullah A. ; Kamal, Magda M. ; Abdelaziz, Lobna M. ; Hafez, Hani M.
Losartan potassium, Valsartan, Telmisartan, and Irbesartan are angiotensin-II-receptor antagonists (ARA II) group, which used in treatment of hypertension alone or in combination with other drugs mainly Hydrochlorothiazide.A gradient HPLC method was developed for the assay of several ARAII in presence of Hydrochlorothiazide.The method was performed by reversed phase high performance liquid chromatog. using a mobile phase 0.025 M potassium dihydrogen phosphate (pH 6.0): acetonitrile = 80:20% with detection at 220 nm on an ACE C18 column (250 mm × 4.6 mm, 5 μm) at flow rate 1.5 mL/min in a gradient manner.The proposed method was validated in terms of linearity, accuracy, precision, and limits of detection and quantitation.
2013-07-01American journal of hypertension3区 · 医学
Dynamic View on Affordability of Fixed-Dose Combination Antihypertensive Drug Therapy
3区 · 医学
Article
作者: Junling Wang ; Jun Tang ; Song Hee Hong
BACKGROUND:
The use of fixed-dose combinations (FDCs) has been increasing since the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure recommended using ≥2 drugs as the first-line drug therapy for patients with stage 2 hypertension. FDCs simplify the drug therapy regimen and reportedly lower the drug therapy cost compared with the free combination (FC) of 2 single-agent drugs. This study hypothesized that the affordability of FDCs over FCs would change over time depending on the availability of generic single-agent drugs.
METHODS:
This study used the 2009 Medical Expenditure Panel Survey. Antihypertensive drugs were identified based on the Food and Drug Administration national drug directory. Based on the 2 databases, regression models were run to predict average monthly drug cost as well as out-of-pocket cost for each prescription along with their 95% confidence intervals (CIs).
RESULTS:
Overall, FDCs (n = 26) had average monthly drug costs similar to respective FCs when FCs were not generically available. However, when FCs were generically available, FDCs (n = 11) had average drugs costs much higher than their respective FCs. For example, Lotrel as an FDC had an average monthly drug cost of $115.97 (95% CI = $96.59-$135.36), whereas its counterpart FC had an average monthly drug cost of $21.00 (95% CI = $18.23-$23.79).
CONCLUSIONS:
The cost advantage of FDCs over FCs was reversed when FCs were generically available. The finding of this study informs patients, health-care providers, and drug plans of the importance of making dynamic decisions on preferred drug therapy options depending on the availability of generic drugs.
2012-09-01Journal of the renin-angiotensin-aldosterone system : JRAAS4区 · 医学
Efficacy and safety of a single-pill fixed-dose combination of high-dose telmisartan/hydrochlorothiazide in patients with uncontrolled hypertension
4区 · 医学
ArticleOA
作者: Shimizu, Tomohiko ; Kuwano, Takashi ; Mitsutake, Ryoko ; Shiga, Yuhei ; Saku, Keijiro ; Nagata, Itsuki ; Shirotani, Tetsuro ; Fujisawa, Kazuaki ; Miura, Shin-ichiro ; Uehara, Yoshinari ; Norimatsu, Kenji ; Arimura, Tadaaki ; Inoue, Asao ; Matsunaga, Eiyu ; Morii, Joji
Objective::
Many patients still have high blood pressure (BP) after treatment with high-dose angiotensin II type 1 receptor blockers (ARBs) or Preminent® (medium-dose of losartan (50 mg/day)/hydrochlorothiazide (HCTZ) (12.5 mg/day)). Therefore, we analyzed whether Micombi®BP (high-dose telmisartan (80 mg/day)/HCTZ (12.5 mg/day)) could provide better results with regard to efficacy and safety for patients with uncontrolled hypertension.
Methods::
In total, 44 hypertensive patients (22 males, age 71±14 years) who showed uncontrolled BP despite the use of high-dose ARBs or Preminent® were enrolled in this study. We used a changeover design in which the patients were switched from high-dose ARBs or Preminent® to Micombi®BP. We analyzed BP, heart rate (HR), and biochemical parameters before and after treatment for 3 months.
Results::
Systolic BP and diastolic BP significantly decreased (125±15/69±11 mmHg) and 85% of the patients achieved their target BP at 3 months after changeover. Patients who switched from ARBs and those who switched from Preminent® showed similar BP-lowering effects. In addition, the reductions in BP after 3 months in patients with or without chronic kidney disease and in those with or without metabolic syndrome (MetS) were also similar. There were no significant changes in HR during the study period. Although blood levels of potassium, hemoglobin A1c and uric acid (UA) significantly increased after 3 months for all of the patients, none of the patients showed serious adverse effects.
Conclusion::
High-dose telmisartan/HCTZ therapy was associated with a significant reduction in BP and helped patients achieve their target BP.
100 项与 替米沙坦氢氯噻嗪 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 原发性高血压 | 欧盟 | 2002-04-19 | |
| 原发性高血压 | 欧盟 | 2002-04-19 | |
| 原发性高血压 | 冰岛 | 2002-04-19 | |
| 原发性高血压 | 冰岛 | 2002-04-19 | |
| 原发性高血压 | 列支敦士登 | 2002-04-19 | |
| 原发性高血压 | 列支敦士登 | 2002-04-19 | |
| 原发性高血压 | 挪威 | 2002-04-19 | |
| 原发性高血压 | 挪威 | 2002-04-19 | |
| 高血压 | 美国 | 2000-11-17 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 132 | (Telmisartan + HCTZ + Amlodipine) | 網淵鬱艱簾築蓋顧選鹽(簾鏇廠選憲廠製鑰願範) = 鑰鏇鏇糧遞鏇構醖構鏇 鹽繭餘網壓夢遞憲衊鹹 (構鏇壓簾夢構積襯淵鬱, 0.8) 更多 | - | 2016-03-28 | ||
placebo+telmisartan + HCTZ (Telmisartan + HCTZ + Placebo) | 網淵鬱艱簾築蓋顧選鹽(簾鏇廠選憲廠製鑰願範) = 選顧醖壓積衊鹽範選衊 鹽繭餘網壓夢遞憲衊鹹 (構鏇壓簾夢構積襯淵鬱, 0.8) 更多 | ||||||
临床3期 | - | 639 | 選網顧鹽醖膚艱糧築選(範鹹蓋廠製壓醖顧鑰製) = occurred in 29 (4.5%) patients 選衊衊遞膚餘壓蓋鬱鏇 (範遞構遞簾網鬱鏇廠觸 ) | - | 2009-02-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用